Post by Medical Device Network

FiberSense has obtained a CE mark for its continuous glucose monitoring (CGM) system, setting the stage for the medical device’s commercialisation in Europe. As with other CGMs, FiberSense’s system is designed for the continuous monitoring of blood glucose levels and glycaemic trends in adults with diabetes. Comprised of an optical sensor and an external detector clip that can be worn for up to 28 days, the company’s device measures glucose concentrations in the subcutaneous tissue fluid and displays them on a paired smartphone app. Popular CGM products from Dexcom and Abbott use electrochemical sensors and are worn for shorter periods. Senseonics’s Eversense 365 lasts up to a year but requires implantation, meaning FiberSense’s technology offers a time period in between the two. FiberSense CEO, Michael Tillman, commented: “After years of intensive development, we are now focusing on scaling up production and commercialisation.” In moving towards commercial readiness, FiberSense highlighted that this will be achieved by focusing on scaling up its production, logistics, customer service, and market access activities for selected launch markets, with the device’s first deliveries to customers anticipated by the end of 2026. #CGM #CEmark #healthcare #diabetes Read the full report below: https://lnkd.in/ed7SqCaQ